MetaCap

Fate Therapeutics (FATE) vs Zura Bio (ZURA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fate Therapeutics (FATE) has outperformed Zura Bio (ZURA) over the past year, losing 10.8% versus a loss of 74.4%. Fate Therapeutics is the larger company by market cap ($111.8 million vs $89.6 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FATE-10.78%ZURA-74.37%
+216%+64%-88%
Nov 21, 20251 yearNov 20, 2026
FATE-82.95%ZURA-96.84%
+58%-23%-104%
Mar 20, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FATE versus ZURA key metrics
MetricFATEZURA
Share price$0.919$0.9305
Market cap$111.82M$89.63M
1-day change-9.01%-2.30%
YTD return-6.22%-82.24%
1-year return-10.78%-74.37%
5-year return-98.25%—
EPS (TTM)$-1.03$-1.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.65M—
Revenue growth (YoY)-51.24%—
Net income (latest FY)$-136.31M$-68.65M
Operating margin-2222.45%—
Net margin-2051.08%—
52-week high$3.23$7.44
52-week low$0.90$0.919
Distance from 52-week high-71.55%-87.49%
Analyst consensusbuystrong_buy
Avg. price target upside+522.42%+759.75%
Average volume1.53M4.47M
Shares outstanding121.67M96.33M
Employees16140
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FATE has outperformed ZURA by 63.6 percentage points over the past year.

About Fate Therapeutics

FATE stock →

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees

About Zura Bio

ZURA stock →

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees

FATE vs ZURA FAQ

Which is bigger, Fate Therapeutics or Zura Bio?

Fate Therapeutics (FATE) is larger, with a market capitalization of $111.82M compared with $89.63M for Zura Bio (ZURA).

Which stock has performed better over the past year, FATE or ZURA?

FATE returned -10.78% over the past 12 months, compared with -74.37% for ZURA (price return, excluding dividends). Past performance does not predict future results.

Are Fate Therapeutics and Zura Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons